Dextromethorphan/Quinidine Improved Symptoms of Pseudobulbar Affect Irrespective of Concomitant Antidepressant Use (P6.210)

Conclusions:In this analysis, DM/Q was associated with PBA symptom improvement regardless of concomitant antidepressant use at baseline.Study Supported by: Avanir Pharmaceuticals, Inc.Disclosure: Dr. Formella has received personal compensation for activities with Avanir Pharmaceuticals, Inc. as an employee. Dr. Alexander has nothing to disclose. Dr. Cutler has received personal compensation for activities with Acadia, Alkermes, Allergan, Arbor Pharmaceuticals, Avanir, Intra-Cellular Therapies, Ironshore, and Lundbeck. Dr. Cutler has received research support from Acadia, Akili, Interactive, Alkermes, Allergan, Avanir, Axsome, Intra-Cellular Therapies, Ironshore, Lundbeck, Medgenics, Neurocrine, Otsuka, Shire, Sunovion, Supernus, and Takeda. Dr. D'Amico has received personal compensation for activities with Avanir Pharmaceuticals, Inc., Sanofi Genzyme, Merck, AstraZeneca, Bristol-Myers, Novartis, and Takeda Pharmaceuticals. Dr. Hammond has received personal compensation for activities with Avanir Pharmaceuticals as an advisor. Dr. Sauve has received personal compensation for activities with Neuroscience Education Institute, Avanir Pharmaceuticals, Inc., Sunovion, Avanir Pharmaceuticals, Inc., and Otsuka as an advisor and speaker. Dr. Zorowitz has received personal compensation for activities with Avanir Pharmaceuticals. Dr. Zorowitz has received personal compensation in an editorial capacity for Archives of Physical Medicine and Rehabilitation, Stroke, and Topics in Stroke Reh...

Source: Neurology - April 17, 2017 Category: Neurology Authors: Formella, A. E., Alexander, D. N., Cutler, A. J., DAmico, S., Hammond, F. M., Sauve, W., Zorowitz, R. D., Siffert, J. Tags: Behavioral and Cognitive Neurology: Emotion/Behavior Source Type: research